<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568529</url>
  </required_header>
  <id_info>
    <org_study_id>XELOX-AGC</org_study_id>
    <nct_id>NCT00568529</nct_id>
  </id_info>
  <brief_title>Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer</brief_title>
  <official_title>Phase II Study on Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and overall survival of the regimen of
      XELOX (Xeloda and oxaliplatin combination) in the patients with relapsed and refractory
      gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The result of treatment in relapsed and refractory gastric cancer is still not satisfactory.
      For the moment, the combination of 5-Fu and cisplatin is regularly used. Capecitabine and
      Oxaliplatin are new generation drugs of 5-Fu and cisplatin. The current study is to evaluate
      the efficacy and toxicity of this combination.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    There are not enough patients enrolled.
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">February 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>2-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression and overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Combine Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XELOX(Xeloda and oxaliplatin combination)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine and Oxaliplatin</intervention_name>
    <description>Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w</description>
    <arm_group_label>Combine Chemotherapy</arm_group_label>
    <other_name>XELOX(Xeloda and oxaliplatin combination)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 70 years

          -  Patients with histologically confirmed, unresectable, recurrent and/or metastatic
             gastric adenocarcinoma

          -  ECOG performance status ≤1

          -  Measurable diseases according to the RECIST

          -  Relapse or refractory after the first-line chemotherapy

          -  Sign ICF,normal laboratory findings:absolute neutrophil count and platelet count ≥
             2.0×109/L and 80×109/L, respectively, hepatic function (total serum bilirubin ≤ UNL,
             transaminases ≤ 1.5 times upper normal limit) and renal function (calculated
             creatinine clearance ≥ 60 ml/min).

        Exclusion Criteria:

          -  Relapse within 6 months after adjuvant chemotherapy which contained oxaliplatin

          -  Have used any of drugs in the regimen in first-line chemotherapy

          -  Pregnant or lactating women,serious uncontrolled diseases and intercurrent infection

          -  The evidence of CNS metastasis

          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix

          -  Received other chemotherapy regimen after metastasis

          -  Participated in other clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Base for drug clinical trials, Fudan University cancer hospital</name_title>
    <organization>Fudan University cancer hospital</organization>
  </responsible_party>
  <keyword>Advanced gastric cancer</keyword>
  <keyword>Response rate</keyword>
  <keyword>Side effects</keyword>
  <keyword>time to progression</keyword>
  <keyword>overall survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

